J&J says its lung cancer drug combination keeps people alive longer

J&J says its lung cancer drug combination keeps people alive longer


Niels Wenstedt | Getty Images

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer.

J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at least a year and possibly longer, J&J executives said in an interview. The company plans to present the full results at a medical meeting later this year.

“This is an absolute igniter,” said Biljana Naumovic, president of U.S. Oncology Solid Tumor at Johnson & Johnson Innovative Medicine. “People were looking for an overall survival difference.”

J&J is trying to supplant AstraZeneca’s blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations and extended the median survival to about three years. These genetic errors cause cancer cells to proliferate. They’re responsible for between 10% and 15% of lung cancer cases in the U.S., according to the American Lung Association.

J&J executives hailed the result as a game-changer that should change the treatment of this type of lung cancer. But there’s no guarantee doctors and patients will all switch to using Rybrevant and Lazcluze since the regimen comes with more side effects and requires infusions every few weeks, said Dr. Stephen Liu, director of thoracic oncology and head of developmental therapeutics at Georgetown University’s Lombardi Comprehensive Cancer Center.

“I think the announcement that this leads to people living longer will force a harder look,” Liu said.

He wants to see who benefited the most so he can treat those patients more aggressively while sparing those who are less likely to respond. Rybrevant and Lazcluze can cause people to develop a rash and lead their fingernails to split.

Like Tagrisso, J&J’s regimen blocks the EGFR protein to prevent cancer cells from growing. It also targets MET, a common pathway cancer uses to develop resistance to drugs.

J&J forecasts Rybrevant and Lazcluze’s annual sales could top $5 billion. Tagrisso brought in about $6 billion for AstraZeneca in 2023.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More